In our study, ERBB2 mutations were detected in 7 patients including 2 (6.1%) in primary tumor tissues, 2 (13.3%) in metastatic tumor tissues, and 3 (5.8%) by ctDNA analysis. Here, ERBB2 is linked to metastatic neoplasm.